Immuneering has dosed the first patient with IMM-6-415 in the P-I/IIa clinical evaluation for the treatment of advanced solid tumors associated with RAF or RAS mutations
The P-I/IIa dose escalation and expansion study assesses the safety, tolerability, PK/PD characteristics as well as RP2D of IMM-6-415 (oral, BID) in the P-I part while the P-IIa part carries out RP2D evaluation in specific tumor arms for the treatment of patients with advanced RAF/RAS mutant solid tumors
IMM-6-415 is a deep cyclic inhibitor (DCI) of the MAPK pathway that demonstrated RAF or RAS mutant tumor growth inhibition both as a monotx. and combination treatment in preclinical studies
Ref: Immuneering | Image: Immuneering
Related News:- Lantern Pharma Reports the First Patient Dosing of LP-184 in the P-I Study for Advanced Solid Tumors Shots: The first patient has been dosed in the P-I trial evaluating the safety & tolerab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
